Samsung Biologics Stock - Sunday background on capacity and pipeline

Samsung Biologics is one of the largest pure-play biologics contract manufacturers worldwide. With no fresh market-moving headlines today, the focus is on a Sunday background look at its capacity build-out, client base and financial profile.

Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 20:58 UTC. Details in the imprint.

Samsung Biologics (KR7207940008) is a leading global contract development and manufacturing organization for biologic drugs based in Incheon, South Korea. With no new market-moving disclosures from Investor Relations or major newswires today, the stock lends itself to a Sunday background review of its capacity, client mix and financial profile.

Scale and role in global biologics

Samsung Biologics describes itself as the world's largest contract manufacturing organization by total bioreactor capacity, with facilities in the Songdo district of Incheon. The site includes four large plants, commonly referred to as Plant 1 through Plant 4, with stainless-steel and single-use bioreactors for monoclonal antibodies and other biologics.

The company reports that total installed manufacturing capacity exceeds 600,000 liters, after the full ramp-up of Plant 4. According to its corporate materials, the long-term plan includes a "Bio Campus II" expansion to further increase capacity and add new modalities such as antibody-drug conjugates and cell and gene therapies.

Client base, services and background

Samsung Biologics operates purely as a contract partner and does not market its own branded medicines, which distinguishes it from vertically integrated pharmaceutical companies. It offers development, clinical and commercial manufacturing, as well as fill-finish services, to global biotech and big pharma clients.

The company is a subsidiary of the Samsung group and plays a strategic role in the conglomerate's healthcare ambitions, alongside Samsung Bioepis in biosimilars. Its Songdo hub has benefited from South Korea's focus on biopharmaceutical exports and the development of a "bio cluster" near Incheon.

Financial profile and recent performance

Samsung Biologics is listed on the Korea Exchange in Seoul and reports its financial results in Korean won. According to the company's 2023 annual report, revenue and operating profit have grown steadily in recent years, driven by higher utilization of existing plants and the ramp-up of newer capacity.

The company highlights a contract backlog that extends over multiple years, providing mid-term visibility on manufacturing volumes. However, as a contract manufacturer, revenue concentration with a limited number of large clients and fluctuations in biotech funding cycles remain structural business risks.

Governance and management background

Samsung Biologics is headquartered in Incheon and overseen by a board that includes executives from the wider Samsung ecosystem. Management emphasizes quality, regulatory compliance and global inspection readiness as core differentiators, given the highly regulated nature of biologic manufacturing.

Regulators such as the US Food and Drug Administration and the European Medicines Agency inspect contract manufacturing facilities to ensure adherence to current Good Manufacturing Practice standards, which is critical for retaining and winning contracts. The company therefore invests steadily in quality systems, digitalization and workforce training.

The product behind the stock

Samsung Biologics generates its revenue by providing end-to-end contract development and manufacturing services for biologic medicines, including monoclonal antibodies and recombinant proteins, rather than selling its own finished drug brands. Clients pay for process development, scale-up and commercial manufacturing capacity.

Where the stock trades today

Shares of Samsung Biologics trade on the Korea Exchange in Seoul under the ticker 207940 in Korean won; the latest verifiable quote and market capitalization data are available via the Korea Exchange and major financial data providers.

Key facts on Samsung Biologics stock

• Company: Samsung Biologics Co., Ltd.
• ISIN: KR7207940008
• Venue: KRX (Korea Exchange)
• Sector / Industry: Health Care - Biotechnology / Biopharmaceutical contract manufacturing

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.